Health brief
Biotech Breakthroughs and Federal Rewrites Shift US Healthcare
The FDA clears Merck's landmark oral cholesterol pill while the White House proposes loosening testosterone prescribing rules.
Health
Merck has successfully turned an injectable biotechnology into a daily pill — a formulation breakthrough that could disrupt the multi-billion-dollar cholesterol therapy market.
BackgroundPCSK9 inhibitors are highly effective drugs that lower low-density lipoprotein cholesterol by blocking a specific liver protein. Until now, all approved PCSK9 therapies required self-injection every few weeks, which limited patient compliance and increased healthcare costs.
- In clinical trials, Lipfendra reduced bad cholesterol by up to 59% in patients with severe genetic hypercholesterolemia, matching the efficacy of injectable rivals.
- The once-daily peptide pill must be taken on an empty stomach to ensure optimal absorption, introducing minor daily compliance rules for patients.
- Merck won approval under an expedited priority review program, positioning the drug to immediately compete against injectable blockbusters from Amgen and Regeneron.
Health
The administration is transforming testosterone from a controlled therapy into a wellness supplement — a regulatory rewrite that could spark a massive surge in hormone prescriptions.
BackgroundTestosterone is classified as a controlled substance due to risks of abuse and cardiovascular side effects, limiting its use to men with serious medical conditions. However, a thriving private market has emerged for age-related symptoms, driving intense political lobbying to ease clinical prescribing rules.
- The FDA proposed rewriting drug labels to allow doctors to prescribe testosterone gels and injections for age-related symptoms like fatigue and low libido, potentially lowering barriers for telehealth startups.
- Defense Secretary Pete Hegseth unveiled a military screening initiative to test active-duty troops for low testosterone levels, framing it as a combat readiness priority that could reshape military health protocols.
- Medical experts warned that widespread deregulation could lead to massive overprescribing, noting that up to 88% of men taking testosterone do not meet clinical guidelines for deficiency.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.